Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery welcomes Dr Scott Pollack as Associate Director of Bioscience

Scott has extensive experience applying biophysics and enzymology to a broad range of drug discovery targets, covering areas ranging from target validation and assay development through to hit identification, characterisation and mechanistic analysis. This experience was gained both from BioFocus (Charles River), where Scott worked for eight years prior to joining Sygnature and the Merck Sharp and Dohme Neuroscience Research Centre, where Scott developed a strong pharmaceutical perspective in these areas, particularly applied to neurodegeneration targets. Scott has a BA in chemistry from Harvard and a PhD in chemistry from the University of California, Berkeley, with research based on catalytic antibodies. He also carried out post-doctoral research on enzymology targets at Harvard.

Latest News

View All

Sygnature Discovery wins Medilink Outstanding Achievement Award

Sygnature Discovery expands DMPK capabilities with acquisition…

Sygnature and RenaSci strengthen drug abuse leadership…

Sygnature Discovery boosts senior management team with…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.